Actuate Therapeutics Inc (ACTU) Stock Ticker
Market factors today
Unlock the full ACTU picture
About Actuate Therapeutics Inc
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.
ACTU stock facts
| Ticker symbol | ACTU |
| Exchange | NASDAQ Global Market |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $16.3M |
| CEO | Daniel Schmitt |
| Employees | 12 |
| Headquarters | Fort Worth, TX, US |
| IPO date | 2024-08-13 |
| Website | actuatetherapeutics.com |
What you can see for ACTU on Tickr
Live ACTU price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the ACTU report.
Rankings
FAQ
What is the ticker symbol for Actuate Therapeutics Inc?
The ticker symbol for Actuate Therapeutics Inc is ACTU, listed on the NASDAQ Global Market.
What is ACTU?
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies,…